

## EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]

Asnis GM, Henderson MA. *Neuropsychiatr Dis Treat*. 2014;10:1911–1923.

On page 1921 “[...] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.

On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis [...]” should be “Both Dey and Mylan’s recent attempts at reanalysis [...]”.

On page 1921 “With over 14 years left in the patent of EMSAM, [...]” should be “with 4 years left in the patent of EMSAM, [...]”.

The authors apologize for these errors.

### Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PscINFO’ database and CAS,

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.